Blockchain out of the Box – Where is the Blockchain in Blockchain-as-a-Service?

Blockchain-as-a-Service (BaaS) is increasingly discussed as a way for companies to get started with blockchain projects. Different BaaS offerings are available, but a systematic categorization of what BaaS comprises is missing. In this research, we analyze the service offerings of BaaS providers based on available online information and identify a number of common characteristics in the BaaS offerings related to the use of service types, distributed ledger technology (DLT) systems, consensus mechanisms, and pricing models. These characteristics are then further analyzed in the light of available literature on BaaS, as well as conducted expert interviews. The objective of this research is to provide an overview of the BaaS landscap,e as well as a taxonomy that provides guid-ance for researchers and practitioners alike interested in BaaS

Commodity prices and intra-household labor allocation

Volatility in commodity markets poses a distinct risk to farmers in developing countries who rely on cash crop agriculture. We combine a time series of international coffee prices with a long-running panel on coffee-growing households in Vietnam to investigate coping mechanisms employed by farmers in a transitioning economy. We find that households cope with lower coffee prices by increasing wage labor of adults with children and adolescents substituting for adults on the farm. Heterogeneity analysis indicates a stronger substitution pattern among women, ethnic minorities, and households with fewer assets. A variety of robustness checks corroborate these findings. Account of this finding should be taken in formulating and implementing social protection and inclusive growth policie

Mobilitetsindeks

I samarbejde med Dansk Industri har Incentive udviklet et mobilitetsindeks, som kan måle den generelle udvikling i mobiliteten i Danmark. Indekset tager udgangspunkt i data om danskernes rejsevaner fra Transportvaneundersøgelsen, og informationer om rejsetider fra Google Maps. Ved hjælp af de to datakilder har vi udviklet et indeks, som kan måle den generelle udvikling i mobiliteten for danskerne. Et af indeksets styrker er, at det er repræsentativt for danskernes rejsemønstre.&nbsp

Anticholinergic therapy for acute asthma in children.

Inhaled anticholinergics as single agent bronchodilators (or in combination with beta(2)-agonists) are one of the several medications available for the treatment of acute asthma in children

Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia:The HypoDeg randomized, controlled, open-label, crossover trial

AIM: To investigate whether the long‐acting insulin analogue insulin degludec compared with insulin glargine U100 reduces the risk of nocturnal symptomatic hypoglycaemia in patients with type 1 diabetes (T1D). METHODS: Adults with T1D and at least one episode of nocturnal severe hypoglycaemia during the last 2 years were included in a 2‐year prospective, randomized, open, multicentre, crossover trial. A total of 149 patients were randomized 1:1 to basal‐bolus therapy with insulin degludec and insulin aspart or insulin glargine U100 and insulin aspart. Each treatment period lasted 1 year and consisted of 3 months of run‐in or crossover followed by 9 months of maintenance. The primary endpoint was the number of blindly adjudicated nocturnal symptomatic hypoglycaemic episodes. Secondary endpoints included the occurrence of severe hypoglycaemia. We analysed all endpoints by intention‐to‐treat. RESULTS: Treatment with insulin degludec resulted in a 28% (95% CI: 9%‐43%; P = .02) relative rate reduction (RRR) of nocturnal symptomatic hypoglycaemia at level 1 (≤3.9 mmol/L), a 37% (95% CI: 16%‐53%; P = .002) RRR at level 2 (≤3.0 mmol/L), and a 35% (95% CI: 1%‐58%; P = .04) RRR in all‐day severe hypoglycaemia compared with insulin glargine U100. CONCLUSIONS: Patients with T1D prone to nocturnal severe hypoglycaemia have lower rates of nocturnal symptomatic hypoglycaemia and all‐day severe hypoglycaemia with insulin degludec compared with insulin glargine U100